Genmab A/S EBIT per Employee
The EBIT per Employee of Genmab A/S (GMAB.CO) as of Sep 27, 2026 is 343,894.84 USD. In the previous year, EBIT per Employee was 1.86 M USD — a change of -81.48% (lower).
Get this data via API
Financial Data API
EBIT per Employee
343,894.84USD
YoY
-81.48%
Last updated:
The Genmab A/S EBIT per Employee history
3 Years
10 Years
25 Years
Max
| YEAR | EBIT per Employee | YoY |
|---|---|---|
| 343,894.84USD | -81.48% | |
| 1.86 MUSD | +31.61% | |
| 1.41 MUSD | -15.61% | |
| 1.67 MUSD | +113.51% | |
| 782,991.88USD | -53.22% | |
| 1.67 MUSD | +139.31% | |
| 699,469.22USD | +91.12% | |
| 365,983.87USD | +2.69% | |
| 356,408.74USD | +27.67% | |
| 279,160.07USD | +44.15% | |
| 193,660.97USD | +175.43% | |
| 70,312.03USD | — |
Genmab A/S Stock analysis
Frequently Asked Questions about Genmab A/S stock
EBIT per Employee of Genmab A/S is 343,894.84 USD in 2026.
EBIT per Employee of Genmab A/S changed from 1.86 M USD to 343,894.84 USD, representing a -81.48% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of EBIT per Employee Genmab A/S since 2006 – with annual values, charts, and detailed analysis.
EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.
EBIT per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's Genmab A/S historically and in real time.
Workforce — Genmab A/S
All Key Metrics — Genmab A/S
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth